Delays to GenSight Biologics’ eye disease gene therapy are leading toward a cash crunch. With the cash runway due to end early next year and Lumevoq still being reviewed in Europe, GenSight is looking ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing ...
GenSight Biologics' cash and cash equivalents totalled €0.6 million as of September 30, 2025, compared to €0.3 million as of June 30, 2025. On October 1, 2025, the company received the net proceeds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback